StocksMedium•7 October 2026•
1 min read
FDA Grants Priority Review to BridgeBio Dwarfism Drug Filing
Key Facts
1The FDA granted priority review to BridgeBio's infigratinib for the treatment of achondroplasia, the most common form of dwarfism.
The FDA granted priority review to BridgeBio's infigratinib for the treatment of achondroplasia, the most common form of dwarfism. Zacks reported that the priority review designation is intended to accelerate the approval process for drugs that offer significant improvements in treating serious conditions.
This regulatory move aims to shorten the FDA approval timeline for what could become the first-in-class oral therapy for the condition. This development follows a period of active economic data, including U.S. initial jobless claims which were reported at 197,000 on October 1, 2026.